- |||||||||| allogeneic umbilical cord-derived mesenchymal stem cells (EN001) / ENCell
An Open-Label, Dose-Escalation, Phase 1a Study to Evaluate Safety, Tolerability, and Exploratory Efficacy of Intravenous Injection of Allogenic Early-Passage Mesenchymal Stem Cells (MSCs), Derived from Wharton's Jelly in the Umbilical Cord, in Patients with Duchenne Muscular Dystrophy () - Apr 21, 2023 - Abstract #ASGCT2023ASGCT_1671;
Conclusions EN001 was safe and well-tolerated at both low-dose (5.0x105 cells/kg) and high-dose (2.5x106 cells/kg) for DMD patients. In addition, the data on treatment efficacy indicates that EN001 improved ambulatory capacity, pulmonary function, and muscle strength in some patients.This study suggests that allogeneic early-passage MSCs derived from Wharton's Jelly might have a potent therapeutic effect for DMD treatment and can be used in all subtype-specific DMD patients.
- |||||||||| allogeneic umbilical cord-derived mesenchymal stem cells (EN001) / ENCell
Trial completion, Enrollment change, Trial completion date: Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD) (clinicaltrials.gov) - Feb 17, 2023
P1, N=7, Completed,
In addition, the data on treatment efficacy indicates that EN001 improved ambulatory capacity, pulmonary function, and muscle strength in some patients.This study suggests that allogeneic early-passage MSCs derived from Wharton's Jelly might have a potent therapeutic effect for DMD treatment and can be used in all subtype-specific DMD patients. Recruiting --> Completed | N=12 --> 7 | Trial completion date: Aug 2028 --> Dec 2022
- |||||||||| allogeneic umbilical cord-derived mesenchymal stem cells (EN001) / ENCell
Trial completion date, Trial primary completion date: Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD) (clinicaltrials.gov) - Apr 28, 2022
P1, N=12, Recruiting,
Recruiting --> Completed | Trial completion date: Dec 2027 --> Dec 2022 Trial completion date: Aug 2027 --> Aug 2028 | Trial primary completion date: May 2022 --> Jan 2023
- |||||||||| allogeneic umbilical cord-derived mesenchymal stem cells (EN001) / ENCell
Trial completion date, Trial primary completion date: Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A (clinicaltrials.gov) - Apr 28, 2022
P1, N=12, Recruiting,
Trial completion date: Aug 2027 --> Aug 2028 | Trial primary completion date: May 2022 --> Jan 2023 Trial completion date: Aug 2027 --> Dec 2027 | Trial primary completion date: May 2022 --> Dec 2022
|
